Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Food Allergenic Extract [EPC]
Diphtherial Respiratory Pseudomembrane Human is a non-standardized allergenic extract used primarily in diagnostic allergy testing and specialized immunotherapy for hypersensitivity management.
Name
Diphtherial Respiratory Pseudomembrane Human
Raw Name
DIPHTHERIAL RESPIRATORY PSEUDOMEMBRANE HUMAN
Category
Non-Standardized Food Allergenic Extract [EPC]
Drug Count
6
Variant Count
6
Last Verified
February 17, 2026
About Diphtherial Respiratory Pseudomembrane Human
Diphtherial Respiratory Pseudomembrane Human is a non-standardized allergenic extract used primarily in diagnostic allergy testing and specialized immunotherapy for hypersensitivity management.
Detailed information about Diphtherial Respiratory Pseudomembrane Human
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Diphtherial Respiratory Pseudomembrane Human.
Diphtherial Respiratory Pseudomembrane Human belongs to a specialized class of biological products known as Non-Standardized Food Allergenic Extracts [EPC]. Despite the 'food' classification in its electronic product code (EPC) category, this specific extract is derived from the complex biological matrix of the pseudomembrane—a thick, leathery, fibrin-rich exudate—formed during a Corynebacterium diphtheriae infection in the human respiratory tract. In the realm of clinical immunology, this substance is utilized as an antigenic source to identify specific IgE-mediated hypersensitivities in patients who may have been exposed to these specific biological proteins.
As a non-standardized extract, this product does not have a defined 'potency unit' (such as BAU or AU) that is recognized by the FDA for standardized extracts like grass pollen or dust mites. Instead, its strength is typically expressed as a weight-to-volume (w/v) ratio or protein nitrogen unit (PNU) concentration. The FDA approval history for non-standardized extracts is rooted in the long-standing clinical use of biological materials to diagnose and treat allergies, falling under the regulatory oversight of the Center for Biologics Evaluation and Research (CBER).
The mechanism of action for Diphtherial Respiratory Pseudomembrane Human is centered on the immunological principle of Type I Hypersensitivity. When a patient is sensitized to the proteins found within the diphtherial pseudomembrane, their immune system produces specific Immunoglobulin E (IgE) antibodies. These antibodies bind to high-affinity receptors (FcεRI) on the surface of mast cells in the skin and basophils in the blood.
Upon diagnostic administration (via skin prick or intradermal injection), the antigens in the extract cross-link the IgE antibodies on the mast cells. This cross-linking triggers a signaling cascade that results in degranulation, the process by which mast cells release inflammatory mediators such as histamine, leukotrienes, and prostaglandins. This localized reaction manifests as a 'wheal' (a raised, itchy bump) and 'flare' (redness), which healthcare providers measure to determine the level of sensitivity. In therapeutic applications (immunotherapy), repeated, escalating doses are thought to shift the immune response from a Th2-dominated (allergic) profile to a Th1-dominated or T-regulatory (Treg) profile, inducing the production of IgG4 'blocking antibodies' that neutralize the allergen before it can trigger IgE-mediated mast cell activation.
Because Diphtherial Respiratory Pseudomembrane Human is administered locally (topically on the dermis or subcutaneously) and is intended to produce a localized immunological response, traditional pharmacokinetic parameters (like those for oral tablets) are not typically measured in the same way.
The primary FDA-recognized uses for Diphtherial Respiratory Pseudomembrane Human include:
This agent is typically available in the following formats:
> Important: Only your healthcare provider can determine if Diphtherial Respiratory Pseudomembrane Human is right for your specific condition. The selection of allergenic extracts requires specialized training in immunology and allergy management.
Dosage for Diphtherial Respiratory Pseudomembrane Human is highly individualized and must be determined by a qualified allergist or immunologist. There is no 'standard' dose, as the concentration is based on the patient's sensitivity level.
Diphtherial Respiratory Pseudomembrane Human may be used in children, but extreme caution is required. Pediatric dosing is generally similar to adult dosing in terms of extract concentration, but the volume injected may be adjusted based on the child's size and the severity of their allergic history. Children are at a higher risk for systemic reactions and must be monitored closely.
No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared through the kidneys in a manner that affects its immunological activity. However, the patient's overall health should be considered if a systemic reaction occurs.
No dosage adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins is localized and does not rely on liver function.
Elderly patients may have reduced skin reactivity, leading to potential false-negative results in skin testing. Furthermore, older adults often have underlying cardiovascular conditions that make the use of epinephrine (required to treat anaphylaxis) more risky. Dosage escalation in immunotherapy should be performed more conservatively in this population.
This medication is never self-administered by the patient at home. It must be administered in a clinical setting equipped to handle anaphylaxis.
In immunotherapy, if a dose is missed, the next dose may need to be reduced depending on how much time has passed.
An overdose of an allergenic extract is defined as the administration of a dose that triggers a systemic allergic reaction or anaphylaxis.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to administer this product yourself without medical guidance.
Most patients receiving Diphtherial Respiratory Pseudomembrane Human will experience some form of localized reaction. These are generally expected and indicate that the immune system is responding to the antigen.
> Warning: Stop taking Diphtherial Respiratory Pseudomembrane Human and call your doctor immediately if you experience any of these symptoms. These may be signs of anaphylaxis, a life-threatening allergic reaction.
There are no known long-term 'toxic' effects of allergenic extracts, as they are biological proteins. However, prolonged immunotherapy (3-5 years) can lead to long-lasting changes in the immune system. In rare cases, patients may develop 'serum sickness-like' reactions (fever, joint pain, rash), though this is more common with heterologous sera than with purified allergenic extracts.
While Diphtherial Respiratory Pseudomembrane Human may not have a specific 'Black Box' in the same format as a synthetic drug, all allergenic extracts carry a standardized FDA warning regarding Anaphylaxis.
Summary of FDA Warning for Allergenic Extracts:
Report any unusual symptoms to your healthcare provider immediately. Even a mild systemic reaction (like sneezing or itching palms) can be a precursor to a more severe event.
Diphtherial Respiratory Pseudomembrane Human is a potent biological agent. Its use is restricted to diagnostic and therapeutic protocols under the direct supervision of a physician. Patients must be informed that while immunotherapy can reduce allergy symptoms over time, it carries an inherent risk of triggering the very allergic symptoms it seeks to treat.
> WARNING: RISK OF ANAPHYLAXIS
> Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients must be observed for at least 30 minutes in a medical facility equipped with emergency supplies. Fatalities have occurred. Patients with severe or unstable asthma are at higher risk.
The most significant risk is a systemic allergic reaction. This is more likely to occur if the patient is symptomatic (e.g., having an active asthma flare or high hay fever symptoms) on the day of the injection. Injections should be postponed if the patient is ill or has a fever.
Patients with poorly controlled asthma (FEV1 < 80% of predicted) should not receive allergenic extracts. Asthma is the primary risk factor for fatal outcomes during immunotherapy.
Patients with pre-existing heart disease may not tolerate the physiological stress of an anaphylactic reaction or the effects of the epinephrine used to treat it.
Most patients can drive after the 30-minute observation period. However, if a patient experiences a systemic reaction or receives antihistamines that cause drowsiness, they should not operate heavy machinery or drive until symptoms have fully resolved and they feel alert.
Alcohol should be avoided on the day of an injection or skin test. Alcohol can increase blood flow to the skin (vasodilation), which may accelerate the absorption of the allergen or exacerbate a local reaction. Furthermore, alcohol can mask the early symptoms of a systemic reaction, such as flushing or lightheadedness.
Immunotherapy is typically a 3-to-5-year commitment. Stopping treatment early may result in the return of allergy symptoms. There is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the protective 'blocking antibodies' will gradually decline over several months.
> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Diphtherial Respiratory Pseudomembrane Human.
For all interactions, the primary strategy is a thorough medication review. If a patient must remain on a beta-blocker for a life-threatening heart condition, the allergist may decide that the risks of immunotherapy outweigh the benefits. For skin testing, a 'washout period' for interfering medications is essential for diagnostic accuracy.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure, heart rhythm, or depression.
Diphtherial Respiratory Pseudomembrane Human must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis include:
Patients allergic to Diphtherial Respiratory Pseudomembrane Human may show cross-reactivity with other Corynebacterium species or related bacterial proteins. There is no known cross-sensitivity with common food allergens unless the extract was prepared in a medium containing food-derived proteins (like soy or yeast).
> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Diphtherial Respiratory Pseudomembrane Human.
FDA Pregnancy Category C (based on general allergenic extract standards). There are no adequate and well-controlled studies in pregnant women.
It is not known whether the allergenic proteins from Diphtherial Respiratory Pseudomembrane Human are excreted in human milk. However, because these are large proteins that are rapidly degraded, it is highly unlikely that they would reach the infant in a bioactive form through breastfeeding. The American Academy of Allergy, Asthma & Immunology (AAAAI) generally considers immunotherapy to be compatible with breastfeeding.
No dosage adjustments are required. The clearance of the immunological response is not dependent on renal filtration. However, patients with end-stage renal disease (ESRD) may have altered immune function and should be monitored for unusual reaction patterns.
No dosage adjustments are needed. The liver does not play a primary role in the processing of subcutaneously administered allergenic proteins.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Diphtherial Respiratory Pseudomembrane Human acts as an exogenous antigen. Its primary molecular targets are the IgE antibodies bound to FcεRI receptors on mast cells and basophils.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Local/Subcutaneous) |
| Protein Binding | Primarily to IgE and APC receptors |
| Half-life (Biological) | 15-30 minutes for skin reaction |
| Tmax (Skin reaction) | 0.25 - 0.33 hours |
| Metabolism | Proteolysis by tissue enzymes |
| Excretion | Lymphatic clearance of fragments |
It is classified as a Non-Standardized Allergenic Extract. It belongs to the broader therapeutic category of Immunotherapy Agents and Diagnostic Biologicals.
Common questions about Diphtherial Respiratory Pseudomembrane Human
Diphtherial Respiratory Pseudomembrane Human is primarily used as a diagnostic tool in allergy skin testing to identify if a person has a specific hypersensitivity to the proteins found in the pseudomembranes caused by diphtheria infections. It may also be used in specialized immunotherapy (allergy shots) to help desensitize a patient to these specific antigens over time. This extract is especially relevant for individuals with potential occupational exposure or rare specific allergies. Because it is a non-standardized extract, its use is typically reserved for specialized immunology clinics. It helps doctors confirm an allergy when a patient's history suggests they react to these specific biological materials.
The most common side effects are localized to the site of administration and include redness, itching, and a raised bump known as a wheal. During a skin test, these symptoms are expected and indicate a positive result, usually fading within an hour or two. For those receiving immunotherapy injections, swelling and soreness at the injection site are frequent and can last for a day or two. Some patients may also experience mild fatigue or a headache shortly after treatment. While these local reactions are common, patients must be monitored for more serious systemic symptoms like hives or difficulty breathing. Always report any reaction that is larger than three inches in diameter to your doctor.
It is strongly recommended that you avoid alcohol on the days you receive a skin test or an immunotherapy injection. Alcohol causes your blood vessels to widen (vasodilation), which can potentially speed up the absorption of the allergen into your bloodstream, increasing the risk of a systemic reaction. Furthermore, being under the influence of alcohol can make it difficult for you to notice the early warning signs of anaphylaxis, such as flushing, warmth, or a rapid heart rate. Alcohol can also worsen the itching and swelling at the injection site. To ensure your safety and the accuracy of the testing, stay hydrated with water instead. Always wait at least 24 hours after your treatment before consuming alcoholic beverages.
Diphtherial Respiratory Pseudomembrane Human is generally not recommended for initiation during pregnancy. While the extract itself is not known to cause birth defects, the risk of a severe allergic reaction (anaphylaxis) in the mother poses a significant danger to the developing fetus by reducing oxygen and blood flow. If a woman is already on a stable maintenance dose of immunotherapy and becomes pregnant, her doctor may decide to continue the treatment at the same or a reduced dose, but they will never increase the dose during pregnancy. Skin testing for diagnostic purposes is also usually postponed until after delivery. If you are pregnant or planning to become pregnant, it is vital to discuss the risks and benefits of this treatment with your allergist. Safety for both the mother and the baby is the top priority.
In the context of diagnostic skin testing, Diphtherial Respiratory Pseudomembrane Human works very quickly, with results typically visible within 15 to 20 minutes of application. For those undergoing immunotherapy (allergy shots), the process is much slower and requires a 'build-up' phase that usually lasts 3 to 6 months. Most patients do not begin to feel a significant reduction in their allergy symptoms until they reach their maintenance dose. The full benefits of the treatment are often not realized until the patient has been receiving the injections for 6 to 12 months. Immunotherapy is a long-term commitment that usually continues for 3 to 5 years to achieve lasting desensitization. Consistent attendance at scheduled appointments is key to the treatment's success.
Yes, you can stop taking Diphtherial Respiratory Pseudomembrane Human immunotherapy injections suddenly without experiencing physical withdrawal symptoms. Unlike some medications that affect the nervous system or hormones, allergenic extracts do not create a chemical dependency. However, stopping the treatment before the recommended 3-to-5-year course is completed will likely result in the return of your allergy symptoms over time. The 'blocking antibodies' your body has built up will gradually decrease, and your sensitivity to the allergen may return to its original level. If you need to stop treatment due to side effects or life changes, discuss a plan with your doctor. They can advise you on whether a temporary break or a permanent discontinuation is appropriate for your situation.
If you miss a scheduled immunotherapy dose of Diphtherial Respiratory Pseudomembrane Human, you should contact your allergist's office as soon as possible to reschedule. Do not attempt to 'double up' on your next dose or take a dose at home. The safety of the next injection depends on the amount of time that has passed since your last one. If only a few days have passed, you may be able to continue with your regular schedule. However, if you have missed several weeks, your doctor will likely need to reduce the dose for your next injection to prevent a severe allergic reaction. Following a strict schedule is the best way to ensure that the treatment is both safe and effective.
There is no scientific evidence to suggest that Diphtherial Respiratory Pseudomembrane Human causes weight gain. The extract consists of small amounts of biological proteins that are injected under the skin or applied to the surface; it does not contain calories, hormones, or metabolic-altering chemicals that would lead to an increase in body fat. If you experience weight changes while undergoing immunotherapy, they are likely due to other factors such as changes in diet, exercise, or other medications you may be taking (like oral corticosteroids for asthma). Some patients may experience temporary swelling at the injection site, but this is localized and not related to systemic weight gain. Always discuss any unexpected changes in your weight with your primary care physician.
Diphtherial Respiratory Pseudomembrane Human can interact with several types of medications, some of which are very serious. Beta-blockers, often used for high blood pressure or heart conditions, are particularly dangerous because they can prevent epinephrine from working if you have a severe allergic reaction. ACE inhibitors and certain antidepressants may also increase the risk or severity of a reaction. If you are undergoing skin testing, you must stop taking antihistamines for several days beforehand, as they will hide the test results. However, most other routine medications for cholesterol, diabetes, or infections do not interfere with the extract. Always provide your allergist with a complete and updated list of every medication and supplement you take.
The concept of a 'generic' does not apply to Diphtherial Respiratory Pseudomembrane Human in the same way it does to chemical drugs like aspirin. Because allergenic extracts are biological products derived from natural sources, each manufacturer's extract is unique based on their specific source material and extraction process. These are classified as 'non-standardized' extracts, meaning there is no single industry-wide standard for their potency. While different laboratories may produce similar extracts, they are not considered interchangeable. Your doctor will typically stick with the same manufacturer's product throughout your treatment to ensure consistency in your dosing. If a switch between manufacturers is necessary, the doctor will usually reduce the dose significantly to ensure your safety during the transition.